Gasmi M, Fillon S, Leriche K, Neisson-Vernant C, Desgranges C
INSERM U271, Unité de Recherche sur les Hépatities, le SIDA et les Rétrovirus Humains, Lyon, French West Indies.
Antivir Ther. 1997 Apr;2(2):91-7.
Zidovudine treatment of human immunodeficiency virus (HIV) infection induces drug-resistant viral strains harbouring specific amino acid substitutions in the reverse transcriptase (RT). To investigate whether this phenomenon could be observed in the case of human T lymphotropic virus type I (HTLV-I) infection, we analysed the HTLV-I RT proviral gene sequence in five HTLV-I/HIV-1 co-infected patients treated with zidovudine for HIV-1 infection and in one untreated co-infected subject. In the 816 bp of HTLV-I pol gene sequence determined, no particular nucleotide mutation associated with zidovudine therapy could be identified in the treated subjects. Moreover, the dominant HTLV-1 deduced amino acid sequences determined in treated subjects were identical to that from the untreated subject. Our data show that in the co-infected patients already presenting well-defined mutations associated with zidovudine resistance in HIV-1, no mutations were observed in a part of the pol gene coding for the RT activity of HTLV-I.
齐多夫定治疗人类免疫缺陷病毒（HIV）感染会诱导产生耐药性病毒株，这些病毒株在逆转录酶（RT）中存在特定的氨基酸替换。为了研究在人类嗜T淋巴细胞病毒I型（HTLV-I）感染的情况下是否能观察到这种现象，我们分析了5例接受齐多夫定治疗HIV-1感染的HTLV-I/HIV-1合并感染患者以及1例未接受治疗的合并感染受试者的HTLV-I RT前病毒基因序列。在所测定的816 bp HTLV-I pol基因序列中，在接受治疗的受试者中未发现与齐多夫定治疗相关的特定核苷酸突变。此外，在接受治疗的受试者中确定的主要HTLV-1推导氨基酸序列与未接受治疗的受试者相同。我们的数据表明，在已经出现与HIV-1中齐多夫定耐药相关明确突变的合并感染患者中，编码HTLV-I RT活性的pol基因部分未观察到突变。
